Doctors Revision

Infectious Diseases

Malaria Prophylaxis and Prevention

Strategies and interventions aimed at preventing malaria infection and disease, including chemoprophylaxis for specific groups, vector control, and community measures.

Also known as: Malaria Prevention, Chemoprophylaxis, IPTp

Open in the interactive guide
On this page

Referral and warning signs

When to refer

Refer travellers seeking prophylaxis advice to appropriate travel clinic or physician knowledgeable about current recommendations.

Red flags

  • Not applicable for prevention topic.

Signs and symptoms

  • Not applicable - Prevention topic.

Risk factors

  • Living in or travelling to malaria-endemic areas.

Diagnosis

Clinical assessment

Not applicable.

Diagnostic criteria

Not applicable.

Management

Non-pharmacological management

  • Vector Control (Reduce Human-Mosquito Contact):
  • - Use of Long-Lasting Insecticide-treated Nets (LLINs): Sleep under an ITN every night. Most effective measure.
  • - Indoor Residual Spraying (IRS): Application of long-acting insecticides to indoor walls/surfaces of homes in targeted areas.
  • - Larval Source Management (LSM): Eliminating or treating mosquito breeding sites (stagnant water).
  • - Personal Protection: Wearing long-sleeved clothing/trousers (especially dusk/dawn), using insect repellents (containing DEET, Picaridin, or IR3535), screening houses.
  • Case Management: Prompt diagnosis and effective treatment of malaria cases reduces parasite reservoir.
  • Health Education: Promoting use of preventive measures, awareness of symptoms, seeking early treatment.

Pharmacological treatment

  • Chemoprophylaxis (Medication to prevent disease): Not routinely recommended for residents of highly endemic areas like Uganda due to cost, adherence issues, resistance risk. Recommended for specific groups:
  • - Pregnant Women (Intermittent Preventive Treatment - IPTp):
  • - Sulfadoxine-Pyrimethamine (SP / Fansidar) 3 tablets single dose.
  • - Given monthly starting from 13 weeks gestation until delivery (at least 3 doses recommended).
  • - Administered as Directly Observed Therapy (DOT) at ANC visits.
  • - Contraindicated in HIV+ women on Cotrimoxazole prophylaxis.
  • - Infants (Intermittent Preventive Treatment - IPTi): SP given alongside routine EPI vaccines at specific ages (policy varies).
  • - Children (Seasonal Malaria Chemoprevention - SMC): Monthly courses of Sulphadoxine-Pyrimethamine + Amodiaquine during high transmission season for children 3m-5y in eligible areas (Sahel region primarily, not standard in Uganda).
  • - Individuals with Sickle Cell Disease: May receive long-term prophylaxis (e.g., Proguanil, SP, Chloroquine - see section 11.1.3).
  • - HIV+ Individuals: Daily Cotrimoxazole prophylaxis provides protection against malaria (and other OIs).
  • - Non-Immune Visitors/Travellers: Require effective chemoprophylaxis before, during, and after travel.
  • - Common options: Atovaquone-Proguanil (Malarone), Doxycycline, Mefloquine. Choice depends on destination resistance patterns, duration, patient factors. Chloroquine generally NOT effective in Uganda due to resistance. (UCG lists Mefloquine). Requires prescription.

Monitoring

Monitor effectiveness of control programs (incidence rates, coverage). Monitor adherence to IPTp/prophylaxis.

Complications

  • Not applicable.

Prevention

  • This entire topic focuses on prevention strategies.

Patient education

  • CRITICAL importance of consistent nightly use of LLINs.
  • Rationale for IRS if implemented in area.
  • Personal protection measures (repellents, clothing).
  • Importance of IPTp for pregnant women.
  • Need for travellers to take appropriate chemoprophylaxis correctly.
  • Seeking prompt diagnosis/treatment if fever develops despite prevention.

Uganda-specific notes

Malaria prevention relies heavily on LLIN distribution and use, IRS in selected districts, and IPTp for pregnant women (using SP, unless on Cotrimoxazole). SMC is not standard policy. Travellers require specific advice (Mefloquine, Doxycycline, or Atovaquone-Proguanil usually recommended).

References

  • Uganda Clinical Guidelines (UCG) 2023

    Chapter 2, Section 2.5.3.4, 2.5.3.5

  • Consolidated Guidelines for the Prevention and Treatment of Malaria in Uganda

    (Latest MOH Malaria Guidelines)

Scroll to Top